chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 0.33
Sex: M
Vaccine: DTAPIPVHIB, PNC13, RV1
Symptoms: No adverse event, Product storage error
Clinical narrative: Child given vaccine that may have had temperature excursion (data logger failure) with stable fridge temps before + after. DOH determine the vaccine to be at risk + advised reporting + revaccination Child had no ill effects thus far
Age: 0.33
Sex: M
Vaccine: DTAPIPVHIB, PNC13, RV1
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 0.33
Sex: F
Vaccine: DTAPIPVHIB, PNC13, RV1
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 0.42
Sex: M
Vaccine: DTAPIPVHIB, PNC13, RV1
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 0.33
Sex: F
Vaccine: DTAPIPVHIB, PNC13, RV1
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (data logger failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination  Child had no ill effects thus far
Age: 0.75
Sex: F
Vaccine: FLU4
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 0.75
Sex: F
Vaccine: FLU4
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (data logger failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination  Child had no ill effects thus far
Age: 0.75
Sex: M
Vaccine: FLU4
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 1.0
Sex: F
Vaccine: FLU4, HEPA
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 1.0
Sex: M
Vaccine: HEPA
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 1.0
Sex: M
Vaccine: HEPA
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (data logger failure) with stable fridge temps before + after. DOH determine the vaccine to be a risk + advised reporting + revaccination Child had no ill effects thus far
Age: 1.0
Sex: F
Vaccine: HEPA
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 1.08
Sex: F
Vaccine: HEPA
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 1.0
Sex: F
Vaccine: HEPA
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child Given vaccine that may have had temperature excursion (Data Logger Failure) with Stable Fridge temps Before & After. DOH determined the vaccine to Be AT Risk & Advised Reporting & Revaccination Child HAD No ill Effects thus FAR
Age: 1.08
Sex: F
Vaccine: FLU4, HEPA
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 1.25
Sex: M
Vaccine: DTAPIPVHIB, PNC13
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (data logger failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination  Child had no ill effects thus far
Age: 1.25
Sex: U
Vaccine: DTAPIPVHIB, FLU4, PNC13
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 8.0
Sex: M
Vaccine: FLU4
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child Given vaccine that may have had temperature excursion (Data Logger Failure) with Stable Fridge temps Before & After. DOH determined the vaccine to Be AT Risk & Advised Reporting & Revaccination Child HAD No ill Effects thus FAR
Age: 1.25
Sex: M
Vaccine: DTAPIPVHIB, FLU4, PNC13
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 1.25
Sex: M
Vaccine: DTAPIPVHIB, PNC13
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 1.25
Sex: F
Vaccine: DTAPIPVHIB, PNC13
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (data logger failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination  Child had no ill effects thus far
Age: 1.5
Sex: M
Vaccine: HEPA
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 1.25
Sex: U
Vaccine: DTAPIPVHIB, PNC13
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child Given vaccine that may have had temperature excursion (Data Logger Failure) with Stable Fridge temps Before & After. DOH determined the vaccine to Be AT Risk & Advised Reporting & Revaccination Child HAD No ill Effects thus FAR
Age: 2.25
Sex: M
Vaccine: HEPA
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 18.0
Sex: M
Vaccine: MNQ, TDAP
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child Given vaccine that may have had temperature excursion (Data Logger Failure) with Stable Fridge temps Before & After. DOH determined the vaccine to Be AT Risk & Advised Reporting & Revaccination Child HAD No ill Effects thus FAR
Age: 11.0
Sex: M
Vaccine: FLU4, HPV9, MNQ, TDAP
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 4.0
Sex: F
Vaccine: DTAPIPV, FLU4
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 1.5
Sex: F
Vaccine: HEPA
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 17.0
Sex: F
Vaccine: MNQ, TDAP
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 18.0
Sex: F
Vaccine: MENB
Symptoms: Product storage error
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination  Child had no ill effects thus far
Sex: M
Vaccine: FLU4
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 4.0
Sex: M
Vaccine: DTAPIPV, FLU4
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far
Age: 11.0
Sex: M
Vaccine: HPV9, MNQ, TDAP
Symptoms: Product storage error
Clinical narrative: Child given vaccine that may have had temperature excursion (data logger failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccinating Child had no ill effects thus far
Age: 11.0
Sex: F
Vaccine: FLU4, HPV9, MNQ, TDAP
Symptoms: No adverse event, Product temperature excursion issue
Clinical narrative: Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination. Child had no ill effects thus far
Age: 12.0
Sex: M
Vaccine: HPV9, MNQ, TDAP
Symptoms: Product storage error
Clinical narrative: ChiLD GiVeN VAcciNE thAt MAY hAVe hAD teMperAtuRe EXCURsioN (Data LOGGeR FAilure) With stABle FriDGe teMps Before + After. Agency determine the VACCiNe to Be At RiSK + ADVISeD Reporting + ReVacciNAtion CHILD HAD NO ill Effects thus FAR
Age: 15.0
Sex: F
Vaccine: HPV4
Symptoms: Product storage error
Clinical narrative: Child Given VAcciNE thAt MAY hAve hAd teMperAture EXCURsioN (DAtAa LOGGeR FAilure) With StABle FriDGe teMps Before + AfteR. Agency determine the VACCiNe to Be At RISK + ADViSED RepoRtiNG + RevACCINAtion ChilD HAD NO ill Effects thus FAR
Age: 22.0
Sex: F
Vaccine: HEP
Symptoms: Pruritus, Rash
Clinical narrative: STAFF COMPLAINED OF RASH AND ITCHINESS ALL OVER HER BODY FEW HOURS AFTER RECEIVING THE HEP B VACCINE. STAFF CALL HER PCP AND WAS ADVISED TO TAKE A CLARITIN. STAFF STATED THAT CLARITIN DID NOT HELP MUCH.
Age: 20.0
Sex: F
Vaccine: UNK
Symptoms: Chills, Cold sweat, Decreased appetite, Diarrhoea, Exposure during pregnancy
Clinical narrative: I?m currently pregnant and due August 1st.  After I got the tetanus shot on May 14th I?ve had chills, no appetite, nausea, diarrhea, severe headache, cold sweats, and now vomiting.
Age: 20.0
Sex: F
Vaccine: UNK
Symptoms: Headache, Nausea, Vomiting
Clinical narrative: I?m currently pregnant and due August 1st.  After I got the tetanus shot on May 14th I?ve had chills, no appetite, nausea, diarrhea, severe headache, cold sweats, and now vomiting.
Age: 39.0
Sex: F
Vaccine: FLU4
Symptoms: Joint range of motion decreased, Musculoskeletal pain, Myalgia, Pain, Product administered at inappropriate site
Clinical narrative: The injection itself did not seem out of the ordinary, other than the nurse used a diffuser pad.  This was my 5th flu vaccination in my liftetime and I was used to the deltoid soreness, however starting that evening, I had actual shoulder pain, not just muscular pain.  I developed a shoulder impingement pattern (painful arc, decreased proprioception resulting in inappropriate glenohumeral/scapulothoracic motor control associated with shoulder motion in function).  I was referred to work comp since the injection happened at work, as part of the hospital regulation that I must have the influenza vaccine.  When I saw the work comp physician he was very familiar with the fact that likely the nurse actually injected the vaccine in my joint and not in my muscle.  My prescribed treatment was anti-inflammatories which only helped when I was on them and some extremely poor physical therapy which was not helpful.  I had consistent pain with arm movement for at least 5 months and had residual pain at times of more significant shoulder exertion for about 13 months from the vaccination.  I asked my work comp physician if he would be reporting my vaccine injury/side effect and he told me no.  This is why I am reporting it now-I learned of this website today and felt it was my duty to personally report this since my physician did not.
Age: 39.0
Sex: F
Vaccine: FLU4
Symptoms: Rotator cuff syndrome
Clinical narrative: The injection itself did not seem out of the ordinary, other than the nurse used a diffuser pad.  This was my 5th flu vaccination in my liftetime and I was used to the deltoid soreness, however starting that evening, I had actual shoulder pain, not just muscular pain.  I developed a shoulder impingement pattern (painful arc, decreased proprioception resulting in inappropriate glenohumeral/scapulothoracic motor control associated with shoulder motion in function).  I was referred to work comp since the injection happened at work, as part of the hospital regulation that I must have the influenza vaccine.  When I saw the work comp physician he was very familiar with the fact that likely the nurse actually injected the vaccine in my joint and not in my muscle.  My prescribed treatment was anti-inflammatories which only helped when I was on them and some extremely poor physical therapy which was not helpful.  I had consistent pain with arm movement for at least 5 months and had residual pain at times of more significant shoulder exertion for about 13 months from the vaccination.  I asked my work comp physician if he would be reporting my vaccine injury/side effect and he told me no.  This is why I am reporting it now-I learned of this website today and felt it was my duty to personally report this since my physician did not.
Age: 53.0
Sex: M
Vaccine: HEP
Symptoms: Pain in extremity, Pruritus, Pyrexia
Clinical narrative: Woke up from sleep at 2:00 am with pain and itching in the immunized arm. Itching in both legs also. Fever of 100 F. Symptoms resolved around 12:00 pm the same day
Age: 32.0
Sex: F
Vaccine: UNK
Symptoms: Immediate post-injection reaction, Mobility decreased, Musculoskeletal pain, Pain, Pain in extremity
Clinical narrative: Immediate pain from left arm after injection. Continuous pain in arm/shoulder since the day of the shot during the day and night. Limited mobility as it is painful to reach for items or hold any weight in left hand. Pain is still continuing. Birth information: Due date is July 30th 2020
Age: 72.0
Sex: F
Vaccine: PPV
Symptoms: Fatigue, Headache, Pain in extremity, Pruritus, Rash macular
Clinical narrative: The evening she got her shot, patient reports headache, fatique, sore arm, red spots and itchiness on arm
Age: 74.0
Sex: F
Vaccine: VARZOS
Symptoms: Arthralgia, Chest discomfort, Erythema, Headache, Palpitations
Clinical narrative: pt  went to the hospital  complaint  about  chest tightness , joint pain , red cheeks , rash , headache and heart palpitation ,  As per pt she  received benadryl shots   since  she cannot take  any steroid and was  stabilized and was  discharged  to home  and she  feeling  better
Age: 74.0
Sex: F
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: pt  went to the hospital  complaint  about  chest tightness , joint pain , red cheeks , rash , headache and heart palpitation ,  As per pt she  received benadryl shots   since  she cannot take  any steroid and was  stabilized and was  discharged  to home  and she  feeling  better
Age: 66.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site discomfort, Injection site erythema, Injection site induration, Injection site pain, Injection site pruritus
Clinical narrative: Began as 3" red rash/welt at injection spot. Red area grew to cover 1/2 of upper arm within 2 days. Red area was hot to the touch and swollen/hard under the skin in some areas. Itching and pain. No fever. Was told to ice the area and take Benadryl. Was also given a prescription for Cephalexin. Benadryl did not seem very effective. Recovery only began once I began the Cephalexin. Within 24 hours the red area began to fade in most areas except the injection spot. Still some slight discomfort and redness as injection spot currently at apx. 106 hours after injection.
Age: 66.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site rash, Injection site swelling, Injection site urticaria, Injection site warmth
Clinical narrative: Began as 3" red rash/welt at injection spot. Red area grew to cover 1/2 of upper arm within 2 days. Red area was hot to the touch and swollen/hard under the skin in some areas. Itching and pain. No fever. Was told to ice the area and take Benadryl. Was also given a prescription for Cephalexin. Benadryl did not seem very effective. Recovery only began once I began the Cephalexin. Within 24 hours the red area began to fade in most areas except the injection spot. Still some slight discomfort and redness as injection spot currently at apx. 106 hours after injection.
Age: 25.0
Sex: F
Vaccine: UNK
Symptoms: Muscle tightness, Urticaria
Clinical narrative: Hives and intention in my lower back where shot was given.
Age: 56.0
Sex: M
Vaccine: RAB
Symptoms: Blood pressure increased, Blood test, Headache, Urine analysis
Clinical narrative: Two days after vaccine was administered I noticed increasing blood pressure and headaches. Four days after vaccine my blood pressure elevated to 180/110 and had to go to the Emergency Room
Age: 1.0
Sex: M
Vaccine: MMR
Symptoms: Rash
Clinical narrative: Full body rash
Age: 67.0
Sex: M
Vaccine: PPV
Symptoms: Erythema, Pain, Swelling
Clinical narrative: red, swollen, pain over large area below the injection site (nothing at the injection site)
Age: 58.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site pruritus, Injection site rash
Clinical narrative: rash and Pruritis  at injection sight started small on 5/16/2020 and grew larger redder and increased pruritis over the next 24 hours. Patient has only taken one dose of benydrl 25mg to help with sleep.   recommendations given:  Apply a cold compress to the site for approximately 15 minutes if the patient has any inflammation/swelling/or soreness. Recommend an analgesic such as acetaminophen or non-steroid anti-inflammatory drug. An anti-histamine can be used for any swelling make sure to observe and discuss with the patient signs of generalized anaphylaxis Apply firm pressure to the site and raise the arm above heart level for excessive bleeding
Age: 30.0
Sex: F
Vaccine: HEP
Symptoms: Cough, Facial pain, Grimacing, Hypoaesthesia, Loss of personal independence in daily activities
Clinical narrative: Within 12-24 hours of my first dose of this HepB vaccination, I developed severe pain in my fingertips, palms of my hands, my face, and the bottom of my feet and toes. Walking, grimacing, coughing, sneezing, washing dishes, fastening clothing, and resting my hands on my steering wheel while driving were excruciating. This pain lasted about 3-4 weeks. My 2nd dose of the HepB vaccination was on 09/25/2019. Within 6-8 hours of this dose, I developed tingling/pins and needles feeling in my right hand, fingers, and arm. Within an hour of this numbness, I lost feeling and sensation in my right arm from my elbow to my fingertips. Overall, this lasted approximately 12 hours, but the pain from the 1st dose started again and continued for another 3-4 weeks.
Age: 30.0
Sex: F
Vaccine: HEP
Symptoms: Pain in extremity, Paraesthesia, Sensory loss, Sneezing
Clinical narrative: Within 12-24 hours of my first dose of this HepB vaccination, I developed severe pain in my fingertips, palms of my hands, my face, and the bottom of my feet and toes. Walking, grimacing, coughing, sneezing, washing dishes, fastening clothing, and resting my hands on my steering wheel while driving were excruciating. This pain lasted about 3-4 weeks. My 2nd dose of the HepB vaccination was on 09/25/2019. Within 6-8 hours of this dose, I developed tingling/pins and needles feeling in my right hand, fingers, and arm. Within an hour of this numbness, I lost feeling and sensation in my right arm from my elbow to my fingertips. Overall, this lasted approximately 12 hours, but the pain from the 1st dose started again and continued for another 3-4 weeks.
Age: 47.0
Sex: F
Vaccine: FLU4
Symptoms: Chest crushing, Chills, Dyspnoea, Pain, Pyrexia
Clinical narrative: great crushing weight on chest, fever, chills, aches, difficulty breathing
Age: 0.33
Sex: M
Vaccine: DTAPIPVHIB, PNC13, RV5
Symptoms: Crying, Diarrhoea, Emotional distress, Faeces discoloured, Mucous stools
Clinical narrative: Patient received his 4 month vaccinations on 4/21/20 at 3:30pm. On 4/26/20 at approximately 5pm, he began having severe persistent diarrhea. Prior to this, he would normally have a bowel movement once every 5-6 days, yellow. Beginning on 4/26/20, his stool became dark green, liquid, mucous-filled. He had several similar stools before bed on 4/26/20 and on 4/27/20 began having 12-15 bowel movements per day. This continued until 5/14/20 (texture and frequency) and since 5/14/20 to present, frequency has changed to 6-8 movements per day and the color is slowly becoming more yellow, but still liquid and mucous-filled. Also beginning 5/24/20, patient has become inconsolable both during the day and at night. He is unable to sleep for more than 30 minutes at a time and wakes screaming and whimpering.
Age: 0.33
Sex: M
Vaccine: DTAPIPVHIB, PNC13, RV5
Symptoms: Poor quality sleep, SARS-CoV-2 test negative, Screaming, Viral test negative
Clinical narrative: Patient received his 4 month vaccinations on 4/21/20 at 3:30pm. On 4/26/20 at approximately 5pm, he began having severe persistent diarrhea. Prior to this, he would normally have a bowel movement once every 5-6 days, yellow. Beginning on 4/26/20, his stool became dark green, liquid, mucous-filled. He had several similar stools before bed on 4/26/20 and on 4/27/20 began having 12-15 bowel movements per day. This continued until 5/14/20 (texture and frequency) and since 5/14/20 to present, frequency has changed to 6-8 movements per day and the color is slowly becoming more yellow, but still liquid and mucous-filled. Also beginning 5/24/20, patient has become inconsolable both during the day and at night. He is unable to sleep for more than 30 minutes at a time and wakes screaming and whimpering.
Age: 0.17
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC13, RV5
Symptoms: Dyspnoea, Respiratory rate increased
Clinical narrative: He started having difficulty breathing and was breathing rapidly, taking lots of fast short breaths. It lasted 4 hours long.
Age: 57.0
Sex: F
Vaccine: FLUC4
Symptoms: Mobility decreased, Pain in extremity
Clinical narrative: Patient returned to the pharmacy and reported that she had issues with her arm since her flu shot I n February. Her arm hurts when and is hard to lift out to her side but she is able to lift it forward with no issue. Also, patient stated her arm hurts while she sleeps Patient reported reaction 4 days after shot given
Age: 0.08
Sex: M
Vaccine: HPV9, HPV9, UNK, HPV9
Symptoms: Crying, Immediate post-injection reaction, Musculoskeletal stiffness
Clinical narrative: Stiffening with crying immediately after injection (per mom)
Age: 0.08
Sex: M
Vaccine: HPV9, HPV9, UNK, HPV9
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: Stiffening with crying immediately after injection (per mom)
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Pain in extremity
Clinical narrative: arm pain; This case was reported by a nurse via call center representative and described the occurrence of pain in arm in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was recovered/resolved.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional details were provided as follows: The age at the vaccination was not reported. The patient received Shingrix and had arm pain and she knew she was not alone because others have too.  The pain lasted for a couple weeks and was significant. She had no reactions after the second dose. The reporter did not consent to follow up. The HCP did not wish to provide any further information regarding this. She declined to provide any further information since she knows this was an expected adverse event following Shingrix administration.
Age: 16.0
Sex: F
Vaccine: MENB, MNQ, MENB, MNQ
Symptoms: Injection site erythema, Injection site swelling
Clinical narrative: Left arm post injection swollen at injection site and red to the elbow.
Age: 30.0
Sex: F
Vaccine: FLUX
Symptoms: Back pain, Joint range of motion decreased, Magnetic resonance imaging, Pain, Shoulder injury related to vaccine administration
Clinical narrative: I had the typical post-vaccine soreness for 2 days but the pain persisted after that and was made worse by certain motions that involved raising my arm or by laying on my left side. I also have limited range of motion and have been developing back pain on my left side. It has been over a year and I still have pain on a daily basis. Diagnosis by orthopedist is SIRVA
Age: 30.0
Sex: F
Vaccine: FLUX
Symptoms: X-ray
Clinical narrative: I had the typical post-vaccine soreness for 2 days but the pain persisted after that and was made worse by certain motions that involved raising my arm or by laying on my left side. I also have limited range of motion and have been developing back pain on my left side. It has been over a year and I still have pain on a daily basis. Diagnosis by orthopedist is SIRVA
Age: 4.0
Sex: F
Vaccine: MMRV, UNK
Symptoms: Accidental exposure to product, Exposure via skin contact, No adverse event
Clinical narrative: No adverse symptoms were reported.; patient moved during administration and some of the vaccine "got on the patient's leg"; some of the vaccine "got on the patient's leg"; she is unsure if the patient received the full dose of PROQUAD.; This spontaneous report was received from a medical assistant, referring to a 4-year-old female patient. The patient's concurrent conditions included seasonal allergies. The patient did not have any pertinent medical history or concomitant therapies.  On 07-MAY-2020, the patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (rHA) (PROQUAD) (lot number S022917 was verified to be a valid lot number, expiration date reported and established as 19-JAN-2021), by subcutaneous route, on the left thigh as prophylaxis (dose and vaccination scheme frequency were not reported). The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot number S038147 was verified to be a valid lot number, expiration date reported and established as 05-JUL-2022).  On the same date, the medical assistant stated that the patient moved during the administration of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (rHA) (PROQUAD) and some of the vaccine got on the patient's leg (accidental exposure to product and exposure via skin contact). Also, she was unsure if the patient received the full dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (rHA) (PROQUAD) (incorrect dose administered). She did not seek medical attention, as the exposure to product occurred at the office visit and was taken care immediately. There were no laboratory diagnostic or studies performed. No adverse symptoms were reported.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Shingles; Information has been received regarding a case in litigation from a lawyer and refers to a female patient of unknown age.  No information was provided regarding medical history, concurrent conditions, or concomitant medications. On or about 16-AUG-2011, the patient was inoculated with zoster vaccine live (ZOSTAVAX) (dose, route, lot # and expiration date was not provided) for the long-term prevention of shingles and zoster-related conditions. Subsequent to zoster vaccine live (ZOSTAVAX) inoculation (date not reported), the patient was treated by a health care provider for shingles. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient has and will continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of shingles was considered not recovered. The event was considered to be related to zoster vaccine live (ZOSTAVAX).
Sex: U
Vaccine: MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: patient received a dose of improperly stored Proquad; no additional adverse effect; This spontaneous case was received from an immunization consultant regarding to a patient of unknown age, gender and ethnicity. The patient's concurrent conditions, medical history, drug allergies and concomitant therapies were not reported.   On 27-JAN-2020, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (lot # S009756 with expiration date on 27-SEP-2020) administered subcutaneously for prophylaxis (strength and dose were not reported). The vaccine was reconstituted with a properly stored sterile diluent. The vaccine was exposed to a temperature between 6 °F and 14 °F (with an average temperature of 11.3 °F) for 12 hours and 30 minutes. No previous temperature excursion was reported. No adverse effect was reported. The report was received due to a data logger.   Albumin status has been verified for measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (lot # S009756) to be recombinant human albumin.  This is one of several reports received from the same source.; Sender's Comments:  US-009507513-2005USA004496: US-009507513-2005USA004621: US-009507513-2005USA004591:
Sex: U
Vaccine: RV5
Symptoms: No adverse event, Product storage error
Clinical narrative: The patient received a dose of the vaccine following temperature excursions on unknown dates; No adverse event; This spontaneous report as received from a medical assistant refers to a current 4-month-old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not provided.   On an unknown date, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ)  (lot # S013439 with expiration date 03-MAR-2021, lot # S013436 with expiration date 30-JAN-2021, and lot # S006050 with expiration date 12-DEC-2020) underwent a temperature excursion.   Temperature Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) Time frame 7 hours 30 minutes Previous temperature excursion? yes, Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) for 8 hours 30 minutes Was call because of a "data logger"? yes  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) at a dose of 2 ml (route not provided) as prophylaxis. No adverse events were reported.  This is one of several reports received from the same reporter  This spontaneous report as received from a other health professional refers to a patient of unknown age.    On an unknown date the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # S006050, 2 milliliter for prophylaxis.       On an unknown date the patient experienced product storage error and no adverse event.    The outcome of product storage error and no adverse event is unknown.   The reporter considered product storage error and no adverse event to be not assessed to Rotavirus Vaccine, Live, Oral, Pentavalent(ROTATEQ).     {Additional information has been requested. / Additional information is not expected.}; Sender's Comments:  US-009507513-2005USA003382: US-009507513-2005USA004545: US-009507513-2005USA004950: US-009507513-2005USA004951: US-009507513-2005USA004952: US-009507513-2005USA004954: US-009507513-2005USA004955: US-009507513-2005USA004956: US-009507513-2005USA004957: US-009507513-2005USA004958: US-009507513-2005USA004959: US-009507513-2005USA004960: US-009507513-2005USA004961: US-009507513-2005USA004962: US-009507513-2005USA004963: US-009507513-2005USA004964: US-009507513-2005USA004965: US-009507513-2005USA004966: US-009507513-2005USA004967: US-009507513-2005USA004968: US-009507513-2005USA004969: US-009507513-2005USA004970: US-009507513-2005USA004971: US-009507513-2005USA004972: US-009507513-2005USA004973: US-009507513-2005USA004974: US-009507513-2005USA004975: US-009507513-2005USA004976: US-009507513-2005USA004977: US-009507513-2005USA004978: US-009507513-2005USA004979: US-009507513-2005USA004980: US-009507513-2005USA004981: US-009507513-2005USA004982: US-009507513-2005USA004983: US-009507513-2005USA004984: US-009507513-2005USA004985: US-009507513-2005USA004986: US-009507513-2005USA004987: US-009507513-2005USA004988: US-009507513-2005USA004989: US-009507513-2005USA004990: US-009507513-2005USA004991: US-009507513-2005USA004992: US-009507513-2005USA004993:
Sex: U
Vaccine: RV5
Symptoms: No adverse event, Product storage error
Clinical narrative: The patient received a dose of the vaccine following temperature excursions on unknown dates; No adverse event; This spontaneous report as received from a medical assistant refers to a current 6-month-old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not provided.   On an unknown date, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ)  (lot # S013439 with expiration date 03-MAR-2021, lot # S013436 with expiration date 30-JAN-2021, and lot # S006050 with expiration date 12-DEC-2020) underwent a temperature excursion.   Temperature Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) Time frame 7 hours 30 minutes Previous temperature excursion? yes, Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) for 8 hours 30 minutes Was call because of a "data logger"? yes  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) at a dose of 2 ml (route not provided) as prophylaxis. No adverse events were reported.  This is one of several reports received from the same reporter  This spontaneous report as received from a other health professional refers to a patient of unknown age.    On an unknown date the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # S006050, 2 milliliter for prophylaxis.       On an unknown date the patient experienced product storage error and no adverse event.    The outcome of product storage error and no adverse event is unknown.   The reporter considered product storage error and no adverse event to be not assessed to Rotavirus Vaccine, Live, Oral, Pentavalent(ROTATEQ).     {Additional information has been requested. / Additional information is not expected.}; Sender's Comments:  US-009507513-2005USA003382: US-009507513-2005USA004545: US-009507513-2005USA004950: US-009507513-2005USA004951: US-009507513-2005USA004952: US-009507513-2005USA004953: US-009507513-2005USA004955: US-009507513-2005USA004956: US-009507513-2005USA004957: US-009507513-2005USA004958: US-009507513-2005USA004959: US-009507513-2005USA004960: US-009507513-2005USA004961: US-009507513-2005USA004962: US-009507513-2005USA004963: US-009507513-2005USA004964: US-009507513-2005USA004965: US-009507513-2005USA004966: US-009507513-2005USA004967: US-009507513-2005USA004968: US-009507513-2005USA004969: US-009507513-2005USA004970: US-009507513-2005USA004971: US-009507513-2005USA004972: US-009507513-2005USA004973: US-009507513-2005USA004974: US-009507513-2005USA004975: US-009507513-2005USA004976: US-009507513-2005USA004977: US-009507513-2005USA004978: US-009507513-2005USA004979: US-009507513-2005USA004980: US-009507513-2005USA004981: US-009507513-2005USA004982: US-009507513-2005USA004983: US-009507513-2005USA004984: US-009507513-2005USA004985: US-009507513-2005USA004986: US-009507513-2005USA004987: US-009507513-2005USA004988: US-009507513-2005USA004989: US-009507513-2005USA004990: US-009507513-2005USA004991: US-009507513-2005USA004992: US-009507513-2005USA004993:
Sex: U
Vaccine: RV5
Symptoms: No adverse event, Product storage error
Clinical narrative: The patient received a dose of the vaccine following temperature excursions on unknown dates; No adverse event; This spontaneous report as received from a medical assistant refers to a current 5-month-old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not provided.   On an unknown date, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ)  (lot # S013439 with expiration date 03-MAR-2021, lot # S013436 with expiration date 30-JAN-2021, and lot # S006050 with expiration date 12-DEC-2020) underwent a temperature excursion.   Temperature Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) Time frame 7 hours 30 minutes Previous temperature excursion? yes, Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) for 8 hours 30 minutes Was call because of a "data logger"? yes  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) at a dose of 2 ml (route not provided) as prophylaxis. No adverse events were reported.  This is one of several reports received from the same reporter  This spontaneous report as received from a other health professional refers to a patient of unknown age.    On an unknown date the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # S006050, 2 milliliter for prophylaxis.       On an unknown date the patient experienced product storage error and no adverse event.    The outcome of product storage error and no adverse event is unknown.   The reporter considered product storage error and no adverse event to be not assessed to Rotavirus Vaccine, Live, Oral, Pentavalent(ROTATEQ).     {Additional information has been requested. / Additional information is not expected.}; Sender's Comments:  US-009507513-2005USA003382: US-009507513-2005USA004545: US-009507513-2005USA004950: US-009507513-2005USA004951: US-009507513-2005USA004952: US-009507513-2005USA004953: US-009507513-2005USA004954: US-009507513-2005USA004956: US-009507513-2005USA004957: US-009507513-2005USA004958: US-009507513-2005USA004959: US-009507513-2005USA004960: US-009507513-2005USA004961: US-009507513-2005USA004962: US-009507513-2005USA004963: US-009507513-2005USA004964: US-009507513-2005USA004965: US-009507513-2005USA004966: US-009507513-2005USA004967: US-009507513-2005USA004968: US-009507513-2005USA004969: US-009507513-2005USA004970: US-009507513-2005USA004971: US-009507513-2005USA004972: US-009507513-2005USA004973: US-009507513-2005USA004974: US-009507513-2005USA004975: US-009507513-2005USA004976: US-009507513-2005USA004977: US-009507513-2005USA004978: US-009507513-2005USA004979: US-009507513-2005USA004980: US-009507513-2005USA004981: US-009507513-2005USA004982: US-009507513-2005USA004983: US-009507513-2005USA004984: US-009507513-2005USA004985: US-009507513-2005USA004986: US-009507513-2005USA004987: US-009507513-2005USA004988: US-009507513-2005USA004989: US-009507513-2005USA004990: US-009507513-2005USA004991: US-009507513-2005USA004992: US-009507513-2005USA004993:
Sex: U
Vaccine: RV5
Symptoms: No adverse event, Product storage error
Clinical narrative: The patient received a dose of the vaccine following temperature excursions on unknown dates; No adverse event; This spontaneous report as received from a medical assistant refers to a current 3-month-old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not provided.   On an unknown date, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ)  (lot # S013439 with expiration date 03-MAR-2021, lot # S013436 with expiration date 30-JAN-2021, and lot # S006050 with expiration date 12-DEC-2020) underwent a temperature excursion.   Temperature Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) Time frame 7 hours 30 minutes Previous temperature excursion? yes, Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) for 8 hours 30 minutes Was call because of a "data logger"? yes  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) at a dose of 2 ml (route not provided) as prophylaxis. No adverse events were reported.  This is one of several reports received from the same reporter  This spontaneous report as received from a other health professional refers to a patient of unknown age.    On an unknown date the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # S006050, 2 milliliter for prophylaxis.       On an unknown date the patient experienced product storage error and no adverse event.    The outcome of product storage error and no adverse event is unknown.   The reporter considered product storage error and no adverse event to be not assessed to Rotavirus Vaccine, Live, Oral, Pentavalent(ROTATEQ).     {Additional information has been requested. / Additional information is not expected.}; Sender's Comments:  US-009507513-2005USA003382: US-009507513-2005USA004545: US-009507513-2005USA004950: US-009507513-2005USA004951: US-009507513-2005USA004952: US-009507513-2005USA004953: US-009507513-2005USA004954: US-009507513-2005USA004955: US-009507513-2005USA004957: US-009507513-2005USA004958: US-009507513-2005USA004959: US-009507513-2005USA004960: US-009507513-2005USA004961: US-009507513-2005USA004962: US-009507513-2005USA004963: US-009507513-2005USA004964: US-009507513-2005USA004965: US-009507513-2005USA004966: US-009507513-2005USA004967: US-009507513-2005USA004968: US-009507513-2005USA004969: US-009507513-2005USA004970: US-009507513-2005USA004971: US-009507513-2005USA004972: US-009507513-2005USA004973: US-009507513-2005USA004974: US-009507513-2005USA004975: US-009507513-2005USA004976: US-009507513-2005USA004977: US-009507513-2005USA004978: US-009507513-2005USA004979: US-009507513-2005USA004980: US-009507513-2005USA004981: US-009507513-2005USA004982: US-009507513-2005USA004983: US-009507513-2005USA004984: US-009507513-2005USA004985: US-009507513-2005USA004986: US-009507513-2005USA004987: US-009507513-2005USA004988: US-009507513-2005USA004989: US-009507513-2005USA004990: US-009507513-2005USA004991: US-009507513-2005USA004992: US-009507513-2005USA004993:
Sex: U
Vaccine: RV5
Symptoms: No adverse event, Product storage error
Clinical narrative: The patient received a dose of the vaccine following temperature excursions on unknown dates; No adverse event; This spontaneous report as received from a medical assistant refers to a current 3-month-old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not provided.   On an unknown date, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ)  (lot # S013439 with expiration date 03-MAR-2021, lot # S013436 with expiration date 30-JAN-2021, and lot # S006050 with expiration date 12-DEC-2020) underwent a temperature excursion.   Temperature Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) Time frame 7 hours 30 minutes Previous temperature excursion? yes, Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) for 8 hours 30 minutes Was call because of a "data logger"? yes  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) at a dose of 2 ml (route not provided) as prophylaxis. No adverse events were reported.  This is one of several reports received from the same reporter  This spontaneous report as received from a other health professional refers to a patient of unknown age.    On an unknown date the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # S006050, 2 milliliter for prophylaxis.       On an unknown date the patient experienced product storage error and no adverse event.    The outcome of product storage error and no adverse event is unknown.   The reporter considered product storage error and no adverse event to be not assessed to Rotavirus Vaccine, Live, Oral, Pentavalent(ROTATEQ).     {Additional information has been requested. / Additional information is not expected.}; Sender's Comments:  US-009507513-2005USA003382: US-009507513-2005USA004545: US-009507513-2005USA004950: US-009507513-2005USA004951: US-009507513-2005USA004952: US-009507513-2005USA004953: US-009507513-2005USA004954: US-009507513-2005USA004955: US-009507513-2005USA004956: US-009507513-2005USA004958: US-009507513-2005USA004959: US-009507513-2005USA004960: US-009507513-2005USA004961: US-009507513-2005USA004962: US-009507513-2005USA004963: US-009507513-2005USA004964: US-009507513-2005USA004965: US-009507513-2005USA004966: US-009507513-2005USA004967: US-009507513-2005USA004968: US-009507513-2005USA004969: US-009507513-2005USA004970: US-009507513-2005USA004971: US-009507513-2005USA004972: US-009507513-2005USA004973: US-009507513-2005USA004974: US-009507513-2005USA004975: US-009507513-2005USA004976: US-009507513-2005USA004977: US-009507513-2005USA004978: US-009507513-2005USA004979: US-009507513-2005USA004980: US-009507513-2005USA004981: US-009507513-2005USA004982: US-009507513-2005USA004983: US-009507513-2005USA004984: US-009507513-2005USA004985: US-009507513-2005USA004986: US-009507513-2005USA004987: US-009507513-2005USA004988: US-009507513-2005USA004989: US-009507513-2005USA004990: US-009507513-2005USA004991: US-009507513-2005USA004992: US-009507513-2005USA004993: